These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19691929)

  • 1. Psoriatic arthritis: pharmacoeconomic considerations.
    Olivieri I; Mantovani LG; D'Angelo S; Padula A; de Portu S
    Curr Rheumatol Rep; 2009 Aug; 11(4):263-9. PubMed ID: 19691929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic issues in psoriatic arthritis.
    Olivieri I; D'Angelo S; Palazzi C; Padula A; Lubrano E; Mantovani LG
    J Rheumatol Suppl; 2012 Jul; 89():103-5. PubMed ID: 22751607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.
    Cortesi PA; Scalone L; D'Angiolella L; Belisari A; Fusco F; Olivieri I; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S126-31. PubMed ID: 23072771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of psoriatic arthritis.
    Ackermann C; Kavanaugh A
    Pharmacoeconomics; 2008; 26(2):121-9. PubMed ID: 18198932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriatic arthritis: treatment strategies using biologic agents.
    D'Angelo S; Palazzi C; Olivieri I
    Reumatismo; 2012 Jun; 64(2):113-21. PubMed ID: 22690388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
    Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
    Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.
    Olivieri I; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Cutro MS; Mathieu A; Matucci-Cerinic M; Pappone N; Punzi L; Scarpa R; Mantovani LG;
    Rheumatology (Oxford); 2008 Nov; 47(11):1664-70. PubMed ID: 18725374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
    Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
    J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic considerations in the treatment of psoriatic arthritis.
    Kavanaugh A
    Rheumatology (Oxford); 2006 Jul; 45(7):790-1. PubMed ID: 16705044
    [No Abstract]   [Full Text] [Related]  

  • 11. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
    Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
    Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriatic arthritis: a dermatologist's perspective.
    Snyder RA
    Am J Clin Dermatol; 2010; 11 Suppl 1():19-22. PubMed ID: 20586501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept in psoriatic arthritis.
    Spadaro A; Lubrano E; Ferrara N; Scarpa R
    J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1303-1312. PubMed ID: 31652079
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of psoriatic arthritis with biological agents.
    Ceponis A; Kavanaugh A
    Semin Cutan Med Surg; 2010 Mar; 29(1):56-62. PubMed ID: 20430309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence.
    Sideris E; Corbett M; Palmer S; Woolacott N; Bojke L
    Pharmacoeconomics; 2016 Nov; 34(11):1101-1110. PubMed ID: 27272887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
    Eder L; Thavaneswaran A; Chandran V; Gladman DD
    Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.